405 related articles for article (PubMed ID: 24880942)
1. Melanoma adjuvant therapy.
Tarhini AA; Thalanayar PM
Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
[TBL] [Abstract][Full Text] [Related]
2. Melanoma adjuvant therapy.
Thalanayar PM; Agarwala SS; Tarhini AA
Chin Clin Oncol; 2014 Sep; 3(3):26. PubMed ID: 25841453
[TBL] [Abstract][Full Text] [Related]
3. Does adjuvant vaccine therapy really have activity in malignant melanoma?
Wheatley K; Ives NJ; Lorigan P
J Clin Oncol; 2007 Oct; 25(29):4693; author reply 4693-5. PubMed ID: 17925569
[No Abstract] [Full Text] [Related]
4. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary treatment of primary melanoma.
Yao K; Balch G; Winchester DJ
Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy for Melanoma.
Agha A; Tarhini AA
Curr Oncol Rep; 2017 May; 19(5):36. PubMed ID: 28417343
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant therapy of malignant melanoma].
Hauschild A; Volkenandt M
Ther Umsch; 1999 Jun; 56(6):324-9. PubMed ID: 10420815
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant therapy of malignant melanoma].
Franke W; Neumann NJ; Ruzicka T; Schulte KW
Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
[TBL] [Abstract][Full Text] [Related]
11. Treatment approaches for advanced cutaneous melanoma.
Stein JA; Brownell I
J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
[TBL] [Abstract][Full Text] [Related]
12. Medical management of melanoma.
Brown CK; Kirkwood JM
Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
[TBL] [Abstract][Full Text] [Related]
13. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.
Tarhini AA; Shin D; Lee SJ; Stuckert J; Sander CA; Kirkwood JM
Melanoma Res; 2014 Apr; 24(2):150-7. PubMed ID: 24509407
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
[TBL] [Abstract][Full Text] [Related]
15. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
[TBL] [Abstract][Full Text] [Related]
16. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.
Agarwala S
Am J Clin Dermatol; 2003; 4(5):333-46. PubMed ID: 12688838
[TBL] [Abstract][Full Text] [Related]
17. [Interferon therapy in malignant melanoma].
Kokoschka EM; Micksche M
Wien Med Wochenschr; 1993; 143(16-17):441-2. PubMed ID: 8273369
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for high-risk primary and resected metastatic melanoma.
Hersey P
Intern Med J; 2003; 33(1-2):33-43. PubMed ID: 12534876
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
20. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
Kirkwood JM; Ibrahim J; Lawson DH; Atkins MB; Agarwala SS; Collins K; Mascari R; Morrissey DM; Chapman PB
J Clin Oncol; 2001 Mar; 19(5):1430-6. PubMed ID: 11230488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
